RxDoctor Payments DataLook up a doctor →

Wade Christensen

Medical · Idaho Falls, IDNPI 1386626463

Payments from drug & device makers

$7,828in general payments, 2019–2025

Across 431 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$599
  • Amgen$534
  • Otsuka America Pharmaceutical, Inc.$408
  • AstraZeneca$326
  • Novartis$301
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$7,68998%
  • Education$1392%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,828 in reported general payments places this provider in the 95th percentile of 265 medical providers in Idaho.

See all medical providers in Idaho

Medicare billing

Part B allowed, 2024
$15,353
Medicare patients
98
Services billed
341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide38$47,544
OzempicSemaglutide45$42,788
Soliqua 100-33Insulin Glargine/Lixisenatide37$36,778
EliquisApixaban31$30,574
MounjaroTirzepatide31$29,601
Tresiba Flextouch U-200Insulin Degludec18$22,927
OxycontinOxycodone Hcl19$21,234
AuvelityDextromethorphan Hbr/Bupropion26$19,536
VraylarCariprazine Hcl12$16,625
GlyxambiEmpagliflozin/Linagliptin24$16,444
Xigduo XrDapaglifloz Propaned/Metformin21$13,287
RybelsusSemaglutide13$13,061
Janumet XrSitagliptin Phos/Metformin Hcl16$11,059
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,248
GemtesaVibegron19$8,863

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$599$77,14569 claims
Novo NordiskOzempic, Rybelsus$280$55,84958 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$270$36,77837 claims
PfizerEliquis$246$30,57431 claims
Axsome Therapeutics, Inc.Auvelity$85$19,53626 claims
AbbVieVraylar, Synthroid$1,367$18,29430 claims
Boehringer IngelheimGlyxambi$161$16,44424 claims
MerckJanumet Xr$77$11,05916 claims
GSKTrelegy Ellipta$147$9,24815 claims
Sumitomo Pharma America, Inc.Gemtesa$31$8,86319 claims
AstraZenecaFarxiga$326$6,28011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 265 medical providers in Idaho.

Other medical in Idaho Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →